Apolipoprotein E (ApoE) Genotype
The ApoE Genotype test identifies which of three common APOE alleles (ε2, ε3, ε4) an individual carries, informing cardiovascular and Alzheimer disease risk. ε4 is associated with elevated LDL cholesterol and markedly increased dementia risk; ε2 confers lower LDL and Alzheimer protection but higher triglycerides.
1
Biomarkers
Blood (whole blood)
Sample
7–10 business days
Turnaround
No
Fasting
What is the ApoE Genotype test?
The Apolipoprotein E Genotype test identifies which of the three common APOE alleles (ε2, ε3, ε4) an individual carries, yielding one of six possible diplotypes. Practitioners order it to refine cardiovascular risk assessment in patients with dyslipidaemia — particularly those whose lipid levels respond unpredictably to diet or medication — and to stratify neurodegenerative risk in patients with cognitive concerns, a family history of Alzheimer disease, or those seeking personalised preventive strategies. Because APOE status modulates both lipid metabolism and brain health, the test bridges cardiology, neurology, and precision medicine. An ε4 result does not diagnose Alzheimer disease but quantifies susceptibility and may prompt earlier surveillance, lifestyle modification, and discussion of emerging therapeutics; an ε2 result highlights triglyceride and remnant lipoprotein monitoring. The test is a risk tool, not a diagnostic one, and must be embedded in appropriate pre- and post-test counselling to manage the psychological and informational complexity of probabilistic genetic results.
What does the ApoE Genotype test measure?
The APOE gene encodes apolipoprotein E, a 299-amino-acid glycoprotein that mediates binding of lipoproteins to cell-surface receptors and plays a central role in cholesterol transport and clearance. Three common alleles — ε2, ε3, and ε4 — arise from single-nucleotide polymorphisms at codons 112 and 158, producing six possible diplotypes. ApoE3 (the ancestral and most frequent form) binds LDL receptors normally; ApoE2 binds poorly and is associated with higher triglycerides and, in homozygotes, type III dyslipidaemia; ApoE4 increases hepatic LDL receptor expression but is linked to higher LDL cholesterol, impaired neuronal lipid homeostasis, and increased Alzheimer disease risk. Beyond lipid metabolism, ApoE isoforms differ in their effects on neuroinflammation, amyloid-beta clearance, and vascular integrity.
ApoE genotyping informs cardiovascular and neurodegenerative risk stratification. Carriers of ε4 exhibit higher LDL cholesterol and greater responsiveness to dietary saturated fat, may benefit from earlier or more intensive lipid-lowering therapy, and face markedly elevated lifetime Alzheimer risk (dose-dependent: one ε4 allele roughly triples risk, two alleles increase it approximately 12-fold in some populations). Conversely, ε2 confers relative protection against Alzheimer but predisposes to hypertriglyceridaemia and, in ε2/ε2 homozygotes with a second metabolic hit, to type III hyperlipoproteinaemia. Genotype results guide personalised dietary and pharmacological strategies and inform discussions of long-term cognitive and cardiovascular risk, though they do not diagnose disease.
Why is the ApoE Genotype test ordered?
- Patients with persistent dyslipidaemia or exaggerated lipid responses to dietary saturated fat, to guide personalised dietary and statin strategies
- Assessment of cardiovascular risk in individuals with a family history of premature atherosclerotic disease or equivocal traditional risk scores
- Evaluation of patients with subjective cognitive decline, mild cognitive impairment, or a strong family history of Alzheimer disease, where ε4 status informs risk and surveillance
- Type III hyperlipoproteinaemia (broad-beta disease) work-up in patients with elevated cholesterol and triglycerides, xanthomas, or premature vascular disease, where ε2/ε2 homozygosity is causative
- Individuals seeking precision health or longevity optimisation who request genetic risk profiling, provided informed consent and counselling are in place
- Patients enrolled in clinical trials or considering emerging Alzheimer therapeutics where APOE status may inform eligibility or monitoring (e.g. amyloid-targeting monoclonal antibodies with ε4-associated ARIA risk)
- Family planning or cascade screening when a proband with early-onset Alzheimer or severe dyslipidaemia carries a high-risk genotype and relatives request testing
Sample collection and turnaround
Sample type
Blood (whole blood)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
7–10 business days
Collection notes
Whole blood collected in EDTA anticoagulant (lavender-top tube) and sent to Boston Heart Diagnostics for genomic DNA extraction and genotyping. Standard phlebotomy precautions; no special preparation. Because this is a genetic test, chain-of-custody and patient identification are critical.
Specimen requirements
Minimum 3–5 mL whole blood in EDTA. Confirm acceptable tube type and stability window with Boston Heart Diagnostics.
What can affect ApoE Genotype results?
Whole-blood specimens can be mislabelled or contaminated; chain-of-custody controls and patient identification are critical to avoid result misattribution in genetic tests.
The assay detects the three common polymorphisms; rare variants or null alleles may not be captured by standard genotyping platforms, potentially misclassifying genotype in a small fraction of cases.
Allele frequencies and effect sizes differ across ancestries — ε4 frequency and Alzheimer risk associations are lower in African and Hispanic populations than in European cohorts — so risk estimates should be interpreted in population context.
Learning ε4 carrier status can provoke anxiety, fatalistic thinking, or premature lifestyle changes; conversely, non-carrier status may create false reassurance. Structured counselling mitigates these effects.
Genotype is fixed, but its phenotypic expression is modified by diet (saturated fat intake amplifies ε4-related LDL elevation), head injury (which interacts with ε4 to raise dementia risk), and statin or PCSK9-inhibitor therapy.
What do ApoE Genotype results mean?
Elevated
Not applicable (result is a genotype, not a level). However, presence of one or two ε4 alleles (ε3/ε4 or ε4/ε4) is associated with elevated LDL cholesterol, heightened dietary saturated-fat responsiveness, and substantially increased Alzheimer disease risk. ε4 homozygotes warrant earlier and more intensive cardiovascular prevention, stricter LDL targets, and discussion of cognitive monitoring and emerging risk-reduction strategies. In the context of amyloid-targeting immunotherapy, ε4 carriers face higher risk of amyloid-related imaging abnormalities (ARIA) and require closer MRI surveillance.
Normal
The ε3/ε3 genotype (present in roughly 50–60 % of most populations) is considered the reference or 'neutral' state, associated with average lipid levels and average Alzheimer risk. It does not confer special protection or vulnerability, and standard cardiovascular and cognitive health guidance applies.
Reduced
Not applicable. However, ε2 alleles (particularly ε2/ε2) are associated with lower LDL cholesterol and reduced Alzheimer risk but higher triglycerides and susceptibility to type III hyperlipoproteinaemia when a second metabolic trigger (obesity, diabetes, hypothyroidism) is present. Homozygous ε2/ε2 individuals require triglyceride and remnant lipoprotein monitoring and may develop palmar or tuberous xanthomas and premature atherosclerosis if dyslipidaemia is untreated.
Note: APOE genotype is one of many factors influencing lipid levels and Alzheimer risk; it is neither necessary nor sufficient for disease. A substantial majority of ε4 carriers do not develop dementia, and Alzheimer disease occurs in non-carriers. Genotype does not change over time, so repeat testing is not needed. Results must be disclosed with pre- and post-test genetic counselling, addressing penetrance, risk magnitude, current evidence for prevention, implications for family members, data privacy, and psychological readiness. This test is not a diagnostic genetic test for familial Alzheimer disease (caused by PSEN1/PSEN2/APP mutations) and should not be conflated with those evaluations.
Frequently asked questions
The test identifies which variants of the APOE gene a person carries, helping stratify risk for cardiovascular disease and Alzheimer disease. It informs personalised lipid management, dietary recommendations, and long-term cognitive health planning but does not diagnose either condition.
How to access the ApoE Genotype test
The ApoE Genotype reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. (2000)
- Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer disease: progress to date and the path forward. Neuron. (2019)
- Genin E, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. (2011)
- American College of Medical Genetics and Genomics (ACMG) policy statement: clinical utility of genetic and genomic services — a position statement of the ACMG. (2015)
- National Institute on Aging and Alzheimer's Association workgroup guidelines for diagnostic evaluation and genetic counselling for APOE testing. (2023)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.